PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6066人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254956, encodeId=326f125495686, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关, objectType=article, longId=134603, objectId=74e21346033e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74e21346033e, replyNumber=0, likeNumber=93, createdTime=2018-04-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74e21346033e, moduleTitle=Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74e21346033e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254955, encodeId=38201254955e3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：震惊！PD-1/PD-L1免疫抑制剂或可出现致死性并发症！, objectType=article, longId=132932, objectId=7c6813293284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c6813293284, replyNumber=0, likeNumber=45, createdTime=2018-03-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c6813293284, moduleTitle=Lancet：震惊！PD-1/PD-L1免疫抑制剂或可出现致死性并发症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c6813293284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254954, encodeId=f446125495466, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BMJ：抗PD-L1药物免疫相关的不良事件！, objectType=article, longId=132477, objectId=327f1324e704, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327f1324e704, replyNumber=0, likeNumber=59, createdTime=2018-03-16, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327f1324e704, moduleTitle=BMJ：抗PD-L1药物免疫相关的不良事件！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327f1324e704)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254953, encodeId=304c12549534d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物, objectType=article, longId=131112, objectId=8a26131112d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a26131112d7, replyNumber=0, likeNumber=74, createdTime=2018-03-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a26131112d7, moduleTitle=JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a26131112d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254952, encodeId=1e451254952a7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：头颈部肿瘤患者血浆PD-L1+外泌体的临床意义, objectType=article, longId=130922, objectId=91761309222a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91761309222a, replyNumber=0, likeNumber=76, createdTime=2018-03-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91761309222a, moduleTitle=CLIN CANCER RES：头颈部肿瘤患者血浆PD-L1+外泌体的临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91761309222a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254951, encodeId=8f6212549516f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗？, objectType=article, longId=130869, objectId=aaa31308691f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaa31308691f, replyNumber=0, likeNumber=74, createdTime=2018-03-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaa31308691f, moduleTitle=J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaa31308691f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254950, encodeId=22b7125495027, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：血管靶向光动力疗法可以增强PD-1/PD-L1通路阻滞抗肿瘤免疫反应, objectType=article, longId=130628, objectId=2e681306281d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e681306281d, replyNumber=0, likeNumber=86, createdTime=2018-02-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e681306281d, moduleTitle=CLIN CANCER RES：血管靶向光动力疗法可以增强PD-1/PD-L1通路阻滞抗肿瘤免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e681306281d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254949, encodeId=5be312549495c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：非小细胞肺癌患者抗PD-1/PD-L1阻断治疗反应的分子决定因素, objectType=article, longId=126847, objectId=ac8812684e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac8812684e25, replyNumber=0, likeNumber=53, createdTime=2018-01-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac8812684e25, moduleTitle=JCO：非小细胞肺癌患者抗PD-1/PD-L1阻断治疗反应的分子决定因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac8812684e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254948, encodeId=6c4d125494840, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature：CD4/6抑制剂通过增加PD-L1表达提高免疫检查点抑制剂的治疗效果, objectType=article, longId=125917, objectId=6df412591ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6df412591ef3, replyNumber=0, likeNumber=54, createdTime=2018-01-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6df412591ef3, moduleTitle=Nature：CD4/6抑制剂通过增加PD-L1表达提高免疫检查点抑制剂的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6df412591ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254947, encodeId=05eb125494e83, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：PD-L1免疫组化检测：NSCLC中的分析及临床应用, objectType=article, longId=124802, objectId=d02e124802f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02e124802f2, replyNumber=0, likeNumber=66, createdTime=2017-12-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02e124802f2, moduleTitle=J Clin Oncol：PD-L1免疫组化检测：NSCLC中的分析及临床应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02e124802f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254946, encodeId=4cb61254946e0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Oncotarget：PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭, objectType=article, longId=124231, objectId=8f861242312e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f861242312e, replyNumber=0, likeNumber=86, createdTime=2017-12-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f861242312e, moduleTitle=Oncotarget：PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f861242312e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254945, encodeId=7ff612549453d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期, objectType=article, longId=123956, objectId=a774123956b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a774123956b5, replyNumber=0, likeNumber=58, createdTime=2017-12-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a774123956b5, moduleTitle=Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a774123956b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254944, encodeId=111112549446f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：头颈部肿瘤患者血浆中PD-L1 +外泌体的临床意义, objectType=article, longId=123725, objectId=e13d123e25fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e13d123e25fc, replyNumber=0, likeNumber=83, createdTime=2017-12-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e13d123e25fc, moduleTitle=Clin Cancer Res：头颈部肿瘤患者血浆中PD-L1 +外泌体的临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e13d123e25fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254943, encodeId=6977125494345, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳, objectType=article, longId=122519, objectId=7e5f122519c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e5f122519c5, replyNumber=0, likeNumber=0, createdTime=2017-12-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e5f122519c5, moduleTitle=JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e5f122519c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254942, encodeId=fa0812549428e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, objectType=article, longId=122363, objectId=cb2d122363b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d122363b2, replyNumber=0, likeNumber=76, createdTime=2017-12-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d122363b2, moduleTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d122363b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达, objectType=article, longId=120620, objectId=7bfc1206208e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bfc1206208e, replyNumber=0, likeNumber=79, createdTime=2017-11-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bfc1206208e, moduleTitle=CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bfc1206208e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254940, encodeId=6567125494014, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Sci Trans Med：科学家给小鼠注射产生PD-L1的干细胞已成功逆转糖尿病！, objectType=article, longId=120352, objectId=c0b012035269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0b012035269, replyNumber=0, likeNumber=0, createdTime=2017-11-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0b012035269, moduleTitle=Sci Trans Med：科学家给小鼠注射产生PD-L1的干细胞已成功逆转糖尿病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0b012035269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254939, encodeId=fc841254939c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性, objectType=article, longId=118912, objectId=d9371189127f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9371189127f, replyNumber=0, likeNumber=143, createdTime=2017-11-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9371189127f, moduleTitle=JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9371189127f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254938, encodeId=c15a12549387a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物, objectType=article, longId=118721, objectId=3b83118e218f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b83118e218f, replyNumber=0, likeNumber=81, createdTime=2017-11-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b83118e218f, moduleTitle=历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b83118e218f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254937, encodeId=fd77125493efb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：PD-L1表达与黑色素瘤免疫逃逸, objectType=article, longId=118029, objectId=117b118029b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117b118029b5, replyNumber=0, likeNumber=83, createdTime=2017-10-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117b118029b5, moduleTitle=CLIN CANCER RES：PD-L1表达与黑色素瘤免疫逃逸, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117b118029b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Int Oral Max Surg：肿瘤PD-L1的表达与年轻女性口腔鳞状细胞癌生存期的改善及复发风险降低有关

2018-04-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：震惊！PD-1/PD-L1免疫抑制剂或可出现致死性并发症！

2018-03-21

仁医06 (审核中...)

前往app查看评论内容

#PD-L1#

BMJ：抗PD-L1药物免疫相关的不良事件！

2018-03-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物

2018-03-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：头颈部肿瘤患者血浆PD-L1+外泌体的临床意义

2018-03-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Thorac Oncol:肺癌胸腔积液细胞PD-L1表达是肺癌患者免疫治疗的预后指标吗？

2018-03-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：血管靶向光动力疗法可以增强PD-1/PD-L1通路阻滞抗肿瘤免疫反应

2018-02-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：非小细胞肺癌患者抗PD-1/PD-L1阻断治疗反应的分子决定因素

2018-01-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature：CD4/6抑制剂通过增加PD-L1表达提高免疫检查点抑制剂的治疗效果

2018-01-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：PD-L1免疫组化检测：NSCLC中的分析及临床应用

2017-12-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Oncotarget：PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭

2017-12-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期

2017-12-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：头颈部肿瘤患者血浆中PD-L1 +外泌体的临床意义

2017-12-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：派姆单抗治疗晚期PD-L1阳性宫颈癌患者效果佳

2017-12-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。

2017-12-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达

2017-11-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Sci Trans Med：科学家给小鼠注射产生PD-L1的干细胞已成功逆转糖尿病！

2017-11-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性

2017-11-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物

2017-11-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：PD-L1表达与黑色素瘤免疫逃逸

2017-10-31

科室
- - 订阅+
  - 更多科室
工具
服务